Table 1.

Correlation between the levels of m⁶A and clinicopathological characteristics in CRC.

Characteristics	No. of patients	Peripheral blood m6A levels % (mean ± SD)	p-value
Age
≤60	57	0.268 ± 0.057	0.649
>60	48	0.273 ± 0.040
Gender
Female	36	0.276 ± 0.064	0.386
Male	69	0.267 ± 0.043
Clinical stage
I	6	0.243 ± 0.031	0.682
II	20	0.263 ± 0.031
III	31	0.260 ± 0.048
IV	26	0.302 ± 0.063
T classification
T1–T2	15	0.268 ± 0.040	0.739
T3–T4	64	0.274 ± 0.056
N classification
N0	29	0.273 ± 0.066	0.933
N1–N2	50	0.272 ± 0.046
N classification
N0–N1	57	0.269 ± 0.056	0.291
N2	22	0.283 ± 0.047
M classification
M0	57	0.260 ± 0.041	<0.001
M1	26	0.302 ± 0.063
Differentiation
Poor	14	0.273 ± 0.030	0.975
Moderate/Well	70	0.273 ± 0.056
Tumor budding
Bd1–Bd2	12	0.262 ± 0.043	0.861
Bd3	16	0.259 ± 0.042
HER2 expression
Negative	26	0.256 ± 0.040	0.368
Positive	26	0.267 ± 0.044
KRAS genotyping
Wild type	10	0.277 ± 0.042	0.360
Mutation type	7	0.299 ± 0.053
BRAF genotyping
Wild type	17	0.279 ± 0.049	0.600
Mutation type	3	0.295 ± 0.031
CEA (ng/ml)
<5	44	0.265 ± 0.040	0.202
≥5	54	0.278 ± 0.057
CA125 (ng/ml)
<35	68	0.269 ± 0.043	0.298
≥35	30	0.280 ± 0.063
CA19-9 (ng/ml)
<35	66	0.271 ± 0.054	0.742
≥35	32	0.275 ± 0.041